Level Four Advisory Services LLC Trims Stock Holdings in AbbVie Inc. $ABBV

Level Four Advisory Services LLC reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 129,118 shares of the company’s stock after selling 4,288 shares during the period. AbbVie comprises 1.0% of Level Four Advisory Services LLC’s portfolio, making the stock its 16th biggest position. Level Four Advisory Services LLC’s holdings in AbbVie were worth $29,896,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter valued at $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the 2nd quarter valued at about $28,000. Caitlin John LLC bought a new position in AbbVie in the 3rd quarter worth about $33,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the second quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC purchased a new position in shares of AbbVie during the second quarter worth approximately $39,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV stock opened at $234.16 on Tuesday. The company has a market cap of $414.04 billion, a P/E ratio of 99.22, a PEG ratio of 0.81 and a beta of 0.34. The stock’s 50-day moving average is $224.47 and its 200 day moving average is $223.47. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on ABBV shares. Citigroup dropped their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Scotiabank initiated coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Finally, Morgan Stanley upped their price objective on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.